Key Highlights

  • Sales rose 4% to USD 498 million and volumes rose 3%, led by growth in Life Sciences and Personal Care.
  • The loss from continuing operations was USD 0.36 per share, while adjusted income excluding amortization was USD 1.12.
  • Adjusted EBITDA rose 2% to USD 121 million, and ongoing free Cash Flow was USD 74 million.
  • Fiscal 2027 outlook is sales of USD 1,905 to 1,975 million and adjusted EBITDA of USD 405 to 435 million.

Fourth-Quarter Results

Ashland Inc. (NYSE:ASH), a global additives and specialty ingredients company, reported fiscal fourth-quarter 2026 sales of USD 498 million for the quarter ended September 30, 2026, up 4% from the prior-year quarter, with sales volumes up 3%. The loss from continuing operations was USD 17 million, or USD 0.36 per diluted share, and the net loss was USD 16 million, or USD 0.35 per share. Adjusted income from continuing operations excluding intangibles amortization expense was USD 52 million, or USD 1.12 per diluted share.

Adjusted EBITDA was USD 121 million, up 2%. Growth in Life Sciences, Personal Care and Intermediates was partly offset by lower Earnings in Specialty Additives. Average diluted shares outstanding were 46 million, unchanged from the prior-year quarter.

Analyst estimates were EPS of USD 1.27 against reported EPS of USD 1.12, and Revenue of USD 501.8 million against reported revenue of USD 498.0 million.

Segment Performance

Chair and Chief Executive Officer Guillermo Novo said the company closed the year with commercial performance in its higher-growth Life Sciences and Personal Care businesses. Life Sciences sales were USD 180 million, up 4%, and pharma achieved its sixth consecutive quarter of year-over-year Volume growth. Personal Care sales were USD 163 million versus USD 151 million, an increase of 8%, with double-digit growth in biofunctional actives, microbial protection and hair care.

Specialty Additives sales were USD 131 million, in line with the prior year, as 9% growth in coatings and 14% growth in performance specialties were offset by lower end-market Demand in energy and resources and lower construction volumes tied to deliberate portfolio actions. Intermediates sales were USD 33 million, also in line.

Cash, Balance Sheet and Fiscal 2027

Cash flows from Operating Activities were USD 90 million in the quarter, and ongoing free cash flow was USD 74 million. For the full fiscal year, ongoing free cash flow was USD 232 million compared with USD 127 million in fiscal 2025. Ashland ended fiscal 2026 with USD 480 million of cash, USD 976 million of total Liquidity and net Debt of USD 891 million.

For fiscal 2027 the company issued an outlook for sales of USD 1,905 million to USD 1,975 million and adjusted EBITDA of USD 405 million to USD 435 million. Management anticipates volatile raw material and freight costs during fiscal 2027, with pricing actions intended to offset anticipated inflation.

Items to Follow in Fiscal 2027

Pharma volume growth, the recovery of construction and energy-related demand in Specialty Additives and the pace of pricing actions against input costs are the items to follow.